Our vision is to enable millions of people each year to restore their pelvic floor, and thereby restore their control, confidence and active lifestyle.
We manufacture innovative pelvic floor muscle strengthening and nerve stimulation products of medical device quality, supported by strong clinical evidence and subjected to controlled product trials. We are at the leading edge of technological developments in muscle rehabilitation and conditioning and are pioneering clinically proven pelvic floor health solutions. Thousands of clinicians and customers rely on Atlantic Therapeutics products such as INNOVO® (www.myinnovo.com) every day, and our products improve many thousands of lives every year. We continue to carry out rigorous clinical trials to support the use of Innovotherapy to treat bladder weakness.
Since launching in March 2016, Innovotherapy has become the leading choice for a safe, effective, home-based treatment for the causes, not just the symptoms, of bladder weakness. Innovotherapy is already available in the UK, France, Germany, Ireland and the Middle East with further launches planned in the near future.
Atlantic Therapeutics’ offices are located in Galway, on the Atlantic coast of Ireland, London, Paris and Salem, close to Lake Constance in Germany.
What is Innovotherapy?
INNOVO® is the only non-invasive pelvic floor exerciser that treats the root cause of bladder weakness – a weak pelvic floor, rather than just managing the symptoms. INNOVO®’s unique Multipath technology uses electrical muscle stimulation (EMS) to deliver 180 perfect and complete pelvic floor contractions to the entire network of pelvic floor muscles in every 30 minute session. It is a proven technology designed to optimally strengthen the pelvic floor and re-educate the muscles that control bladder function.
The new & improved INNOVO® is super simple to use, just pull it on like a pair of cycling shorts and let INNOVO® do the hard work for you. A hand-held controller connects to the shorts and allows the user to increase the intensity of the stimulations - feel your entire pelvic floor lifting & releasing!
INNOVO® treats Stress, Urge & Mixed Incontinence in both women and men, and is used in the comfort of your home. Best of all, INNOVO® is clinically proven to work, with results in as little as 4 weeks!1
of users saw a significant improvement after 4 weeks1
of users saw were defined as dry or near dry after 12 weeks1
of users would recommend the therapy to others2
Who is affected by bladder weakness?
FDA Grants DeNovo Clearance to Atlantic Therapeutics for INNOVO® Therapy Device to Treat Stress Urinary Incontinence
We're excited to announce that the U.S. Food and Drug Administration (FDA) has granted a DeNovo clearance for the INNOVO® therapy device, an externally worn electrical muscle stimulator for the treatment of stress urinary incontinence in adult females.Read More
A non-invasive, clinically proven therapy
All you need to know about the pelvic floor
What is INNOVO®, how does it work, and why do you need it if you’re trying to overcome bladder weakness once and for all? Our short video explains everything.
Atlantic Therapeutics is proud to work with knowledgeable, driven partners to give us the best possible understanding of local market needs and to provide our customers with the highest possible level of service.
For information about how you can access Innovotherapy in your country, please contact us.
If you are interested in joining Atlantic Therapeutics’ distribution network as we introduce our clinically proven, safe and effective treatment globally, please contact us through email@example.com.
We know that bladder weakness is a difficult subject to bring up, so at Atlantic Therapeutics we’re keen to support and reward ambassadors who are open to discussing and promoting a clinically proven solution that will help to improve their customers’ quality of life. Contact us today to find out how you can join Atlantic Therapeutics growing network of Innovotherapy Ambassadors.
Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. All Atlantic Therapeutics Group Ltd. products are certified under the European Medical Devices Directive 93/42/EEC.
Atlantic Therapeutics Group Ltd, has recently successfully completed a €15 million growth capital financing, enabling the company to move forward with the next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence.
The funds come from a combination of venture capital investment from Seroba Life Sciences and Earlybird Venture Capital, as well as Bio-medical Research Group Ltd (previous owner) which retains a minority shareholding. The capital enables Atlantic Therapeutics to accelerate growth from INNOVO® technology platform via market and geographic expansion and new product development.
Board of Directors
Mr Gordie Nye, Chairman of the Board
Mr Steve Atkinson, Chief Executive Officer
Mr Padraic Clarke, Chief Financial Officer
Dr Daniel O’Mahony, Partner with Seroba Life Science
Thom Rasche, Partner at Earlybird
Dr Bernard Collins, Chairman of Biomedical Research
Medical Advisory Board Members
Professor Linda Cardozo is an internationally recognised key opinion leader, Professor of Urogynaecology and Consultant Gynaecologist at King's College Hospital, London
Professor Roger R Dmochowski is Professor at the Department of Urology and Director of the Section of Female Pelvic Medicine at Vanderbilt University in Nashville
Willy Davila, MD,is Chairman of the Department of Gynecology and Head of Urogynecology and Reconstructive Pelvic Surgery at Cleveland Clinic Florida in Weston, Florida; Center Director for the Women's Health Institute in Weston and Clinical Director of Global Patient Services (GPS) for Cleveland Clinic Florida.
Associate Professor Ruth Maher is based at the Department of Physical Therapy, Creighton University in Omaha, and co-Inventor of INNOVO®
Sonja Soeder is Head of the German Pelvic floor centre in Berlin, the largest Physiotherapy centre in Germany
David Kaysen is ex-CEO of Uroplasty, Diametrics Medical and Compex Technologies and is on the board of Cefaly. Dave has extensive experience in the clinical application and commercialization of neuromodulation therapies
Michael Gambla MD, Urologist’ Dr. Michael Gambla, MD is an urology specialist in Columbus, OH and has been practicing for 22 years. He graduated from Rush University in 1996.
Peter Sand MD, Gynaecologist. Dr. Sand has over 100 scientific publications in the medical literature, is the editor of three textbooks on Urodynamics and the Evaluation of Female Incontinence and serves as the secretary/treasurer of the International Urogynecologic Association and Associate Editor of the International Urogynecology Journal. Dr. Sand is also director of the Evanston Continence Center and the Continence Center at Stone Medical Building. He is a national authority on the evaluation and treatment of lower urinary tract problems in women and a recognized expert on pelvic surgery
Diane Newman MD, Gynaecologist. Associate Professor of Urology in Surgery, Perelman School of Medicine, Univeristy of Pennsuylvania. She is Co-Director of the Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Medical Center, in Philadelphia.
Ash Monga, has been a consultant gynaecologist and sub-specialist urogynaecologist in the Southampton University Hospital Trust since 1997. He was the first person to go through the Royal College of Obstetricians & Gynaecologists sub-specialty training in urogynaecology. This led to his main interest in the area of the pelvic floor, including urinary incontinence, prolapse and faecal incontinence. Mr Monga has been a member of the Royal College of Obstetrician and Gynaecologists since 2006. He was Chairman of the Meetings Committee of the British Society of Urogynaecology and then Secretary of the British Society of Urogynaecology. He serves on the Standardisation Committee of the International Incontinence Society and has just finished his term of Chairman of the Publications Committee of the International Urogynaecology Association.